Hepatitis B News and Research

Latest Hepatitis B News and Research

EU requirement for HIV, hepatitis screening of ART couples at each donation unnecessary, distressing

European legislation that requires all couples undergoing assisted reproduction treatment (ART) to be screened for HIV and hepatitis at the time of every sperm or egg donation is unnecessary, expensive, and potentially distressing for patients, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard Monday.

2 Jul 2010

Clemizole can yield high-level synergy with protease inhibitor class: Research

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".

2 Jul 2010

Virus related to hepatitis C discovered in Asian bats

Viral hepatitis affects more than 500 million people worldwide and is a cause of liver failure and liver cancer. While vaccines are available for hepatitis A and B, this is not the case for hepatitis C, which affects as much as two percent of the population in the U.S. Scientists today are reporting discovery of a virus related to hepatitis C in Asian bats, which may provide insights into the origins of the hepatitis C virus and into the mechanisms by which infectious diseases move from other species to humans.

2 Jul 2010

New formula may speed up organ allocation process, improve transplant outcomes

Only a small fraction of transplant centers nationwide are willing to accept and transplant deceased-donor kidneys that they perceive as less than perfect, leading to lengthy, organ-damaging delays as officials use a one-by-one approach to find a willing taker.

2 Jul 2010

Ecolab launches Virasept to treat Clostridium difficile spores

Ecolab Inc. today announced the launch of Virasept, Ecolab's first ready-to-use (no mixing required) hard surface disinfectant approved by the U.S. Environmental Protection Agency to be effective against Clostridium difficile spores.

1 Jul 2010

Call for incorporation of scientific evidence into illicit drug policies

Three leading scientific and health policy organizations today launched a global drive for signatories to the Vienna Declaration, a statement seeking to improve community health and safety by calling for the incorporation of scientific evidence into illicit drug policies. Among those supporting the declaration and urging others to sign is 2008 Nobel Laureate and International AIDS Society (IAS) Governing Council member Prof. Fran-oise Barr--Sinoussi, co-discoverer of HIV.

30 Jun 2010

Repeated viral screening for ART patients unnecessary with each donation

30 Jun 2010

UCLA School of Dentistry awarded NIH grant to study methamphetamine's oral, dental health consequences

The abuse of methamphetamine - a powerful and highly addictive psychostimulant that is toxic to the nervous system - has reached epidemic proportions in many parts of the United States. The National Institute on Drug Abuse estimates that more than 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.

30 Jun 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

Today, world renowned experts have assembled in Dubrovnik, Croatia to discuss the latest trends in treatment and cutting edge research in diagnostic techniques that will shape the future management of hepatocellular carcinoma - the third most common cause of cancer-related death globally, and a leading cause of death among patients with liver cirrhosis.

28 Jun 2010

New affiliation formed to accelerate nation's progress in fighting HIV/AIDS

Two leading institutions in public health and health policy are joining forces to accelerate the nation's progress in fighting HIV/AIDS, hepatitis C and tuberculosis in Washington – the Forum for Collaborative HIV Research and the University of California, Berkeley, School of Public Health.

28 Jun 2010

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

OraSure Technologies, Inc. announced today that its OraQuick Hepatitis C Rapid Antibody Test has been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies in venous whole blood specimens, making it the first rapid HCV test approved by the FDA for use in the United States.

28 Jun 2010

FDA approves OraQuick HCV Rapid Antibody Test for HCV

The U.S. Food and Drug Administration today announced approval of the first rapid blood test for antibodies to the hepatitis C virus for individuals 15 years and older.

25 Jun 2010

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B. But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients' lives.

25 Jun 2010

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.

24 Jun 2010

ABL to host CRP-Santé COMET subtyping tool within TherapyEdge servers

The licensing and distribution agreement allows ABL to directly host COMET (COntext-based Modeling for Expeditious Typing) subtyping tool developed at CRP-Santé within the TherapyEdge servers; it will mainly interact with the ViroScore Suite system to characterize HIV-1 virus subtypes.

24 Jun 2010

Mobile, supervised drug use units considered cost effective: Report

Drug abuse experts believe Melbourne needs a mobile, supervised drug injecting van. This is mainly due to the geographical spread of drug abusers in the region.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Incidence of blood based deficiencies is strong predictor of poor outcome in pSS patients: Study

For healthcare professionals diagnosing primary Sj-gren's Syndrome (pSS, an autoimmune disorder in which immune cells attack and destroy moisture-producing glands), the incidence of blood based deficiencies is the strongest predictor of a poor outcome in patients according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

19 Jun 2010

Hepatitis B News and Research

Latest Hepatitis B News and Research

EU requirement for HIV, hepatitis screening of ART couples at each donation unnecessary, distressing

Clemizole can yield high-level synergy with protease inhibitor class: Research

Virus related to hepatitis C discovered in Asian bats

New formula may speed up organ allocation process, improve transplant outcomes

Ecolab launches Virasept to treat Clostridium difficile spores

Call for incorporation of scientific evidence into illicit drug policies

Repeated viral screening for ART patients unnecessary with each donation

UCLA School of Dentistry awarded NIH grant to study methamphetamine's oral, dental health consequences

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

New affiliation formed to accelerate nation's progress in fighting HIV/AIDS

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

FDA approves OraQuick HCV Rapid Antibody Test for HCV

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

ABL to host CRP-Santé COMET subtyping tool within TherapyEdge servers

Mobile, supervised drug use units considered cost effective: Report

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Incidence of blood based deficiencies is strong predictor of poor outcome in pSS patients: Study

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis B News and Research

Latest Hepatitis B News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in